- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01056224
Effect of Remifentanil Boluses on Hemodynamics in Skull Pin Insertion
The Dose Effects of Remifentanil Boluses on the Hemodynamic Response to Skull Pin Insertion.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Skull pin insertion is commonly required for craniotomies and cervical spine surgery. It is a brief but highly stimulating maneuver performed following induction, during a period of light anesthesia, and may cause significant rise in blood pressure, heart rate and intracranial pressure if not anticipated and treated.
A wide variety of methods have been shown to be effective at blunting this hypertensive response. These include intravenous agents such as fentanyl, sufentanil, clonidine, ketamine and magnesium sulphate, local anesthetic methods such as injection at pin sites or full scalp blocks, deepening the volatile agent, oral premedication or a combination of these methods. There is no consensus on which of these methods is the best. Many anesthesiologists simply use boluses of propofol - a reliable way of accomplishing this effect with a familiar drug. It is also very common for anesthesiologists to use remifentanil, by increasing the infusion rate and or bolusing.
Remifentanil is an ultra-short acting opiate with such rapid onset and offset, that it is most easily and safely delivered by infusion. Increasingly in the literature, however, are reports of remifentanil administered as boluses rather than infusions. Boluses may be ideal for very short stimulating procedures such as intubation and skull pin fixation where a quick onset and offset are desired. Although the safety of bolusing remifentanil has been established in many studies , some authors are still apprehensive . Care must be taken to avoid bolusing with greater doses than required since this may lead to bradycardia and hypotension. In non-ventilated patients, respiratory depression is common and chest wall rigidity may occur at doses larger than 4ug/kg9.
Different bolus dose-effect studies have recommended the following for remifentanil in a variety of clinical settings:
- 3-5ug/kg with propofol 2mg/kg for intubation without muscle relaxants ,
- 2ug/kg with propofol TCI (>4ug/ml) and cisatracurium for intubation (no additional hemodynamic benefit using 4ug/kg)
- 1-1.25ug/kg for rapid sequence intubation with thiopentone 5-7mg/kg and succinylcholine 1mg/kg
- ED50 of 1.7ug/kg and ED95 of 2.88ug/kg for good to excellent intubating conditions in both infants and children (when used with 10ug/kg glycopyrrolate and 4mg/kg propofol)
- 3ug/kg (plus 4mg/kg propofol) provides similar intubating conditions when used in place of succinylcholine 2mg/kg for intubation in infants8
Remifentanil is not currently recommended for the following settings:
- As a sole agent for loss of consciousness with a high ED50 of 12ug/kg, lack of reliability and muscle rigidity common at such high doses
- Wide interindividual variability limit its use for labor analgesia (0.2-0.8ug/kg, median dose of 0.4ug/kg)
In neurosurgery, it is common to administer remifentanil as an infusion. Optimal infusion rates have already been investigated for intracranial surgery . However it is increasingly common to administer remifentanil as a bolus particularly during skull pin fixation, due to the desirable quick onset and offset, and there are no studies at present that have investigated optimal dose requirements for boluses in this setting.
At our institution we commonly administer remifentanil as a bolus during skull pin fixation and are interested in determining which bolus doses are safe and effective
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Toronto Western Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients requiring skull pin fixation and general anesthesia for:
- Elective cervical spine surgery
- Elective craniotomies/brain tumor resection
- Elective transsphenoidal pituitary hypophysectomies
Exclusion Criteria:
Patients with evidence of raised intracranial pressure:
- GSC < 15
- Radiological evidence of significant rise in ICP (e.g. midline shift)
- Vascular anomalies in the brain
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: 1.25 ug/kg normo-tensive 20-40 year olds
A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1.5 ug/kg normo-tensive 20-40 year olds
A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1.75 ug/kg normo-tensive 20-40 year olds
A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1 ug/kg normo-tensive 65-75 year olds
A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1.25 ug/kg normo-tensive 65-75 year olds
A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1.5 ug/kg normo-tensive 65-75 year olds
1.5 ug/kg normo-tensive 65-75 year olds A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old. |
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1 ug/kg hyper-tensive 65-75 year olds
A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1.25 ug/kg hyper-tensive 65-75 year olds
A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
|
Eksperimentell: 1.5 ug/kg hyper-tensive 65-75 year olds
A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
|
A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
To validate the safety and effectiveness of using remifentanil as a bolus for skull pin fixation
Tidsramme: 10 minutes
|
10 minutes
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
To determine the optimal doses for remifentanil in order to blunt the hemodynamic changes associated with skull pin fixation
Tidsramme: 10 minutes
|
10 minutes
|
|
to assess variability in dose requirements of remifentanil
Tidsramme: 10 minutes
|
10 minutes
|
|
to compare the dose effects in younger (20-40yo) vs. older (65-75yo) age groups
Tidsramme: 10 minutes
|
10 minutes
|
|
to compare the dose effects in older (65-75yo) age groups in hypertensive versus non-hypertensive patients
Tidsramme: 10 minutes
|
10 minutes
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Atul Prabhu, MD, University Health Network, Toronto
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 05-0684-B
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .